CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
lomitapidedrug
Likely dose
lomitapide 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01915771
NCT01915771Phase 1Completed

A Phase 1, Open-label, Crossover Study to Determine the Intra-subject Variability of the Pharmacokinetics of Single Oral CapsuleDose of 20 mg Lomitapide in Healthy Subjects

Aegerion Pharmaceuticals, Inc.·interventional·Posted Aug 5, 2013·Updated Mar 11, 2020

In Brief

A Phase 1 clinical trial evaluating lomitapide for Intra-subject Variability of Pharmacokinetics. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Objectives: To evaluate the intra-subject variability of the pharmacokinetics (PK) of single oral capsule doses of 20 mg lomitapide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 5, 2013
Enrollment StartJul 29, 2013
Primary CompletionAug 23, 2013
TodayJul 2, 2026
Enrollment to primary: 24 daysPosted 12.9 years ago

Interventions

lomitapidedrug

20 mg dose